From Algorithm to Phase III: How One Company Nominated 11 Drug Candidates in 10 Months Using AI
Insilico Medicine's executives are taking the stage at global conferences to showcase a record-breaking year that saw the first fully AI-discovered drug reach late-stage trials.
The promise of artificial intelligence in drug discovery is rapidly transitioning from theoretical potential to clinical reality. Insilico Medicine, a company at the forefront of this transformation, has achieved what may be the most tangible validation yet: 11 preclinical candidate nominations in just the first 10 months of 2026, alongside the advancement of what it describes as the world's first fully generative AI-discovered drug into Phase III trials.
Throughout November 2026, Insilico executives will present these achievements at high-profile conferences spanning Shanghai, Nanchang, and Dubai, offering a window into how AI-driven platforms are reshaping pharmaceutical development timelines.
A Record-Breaking Year for AI-Driven Discovery
Insilico Medicine's 11 preclinical candidate (PCC) nominations between January and October 2026 represent a new annual record for the company, bringing its cumulative total to 35 PCCs since 2021. This accelerated output demonstrates what the company characterizes as reproducible efficiency gains through its integrated AI platforms—Pharma.AI, PandaOmics, and Chemistry42—which span target discovery through molecular generation.
The company has also achieved eight clinical milestones across its internal and partnered pipelines as of mid-August 2026, signaling that AI-discovered molecules are successfully navigating the validation required for human testing.
Dr. Jue Wang, Head of Global Business Development, will discuss these developments at the China Healthcare Summit in Shanghai on November 3, 2026. The summit is co-hosted by BioCentury, BayHelix, and McKinsey & Company.
Rentosertib: The First Fully AI-Discovered Drug in Phase III
The centerpiece of Insilico's clinical progress is Rentosertib (ISM001-055), which has entered Phase III trials for idiopathic pulmonary fibrosis (IPF). Described by the company as the world's first fully generative AI-discovered drug candidate with first-in-class potential, Rentosertib represents a pivotal milestone in demonstrating that AI can generate novel molecules capable of progressing through the complete clinical development pathway.
Dr. Feng Ren, Co-CEO and Chief Scientific Officer, will present on these advances at the Future Healthcare Investment Market (FHIM) in Shanghai on November 4, 2026, and at the Chinese Pharmaceutical Association Medicinal Chemistry Symposium (CMCS2026) in Nanchang on November 7, 2026.
The advancement to Phase III trials validates that AI-discovered molecules can meet the safety and efficacy standards required for late-stage development, potentially accelerating treatment options for difficult-to-treat conditions like IPF.
Global Stage for AI Drug Discovery
Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, will address the Next Generation Medicine Congress 2026 in Dubai on November 7, 2026, bringing the company's AI-driven drug discovery insights to an international audience.
Additionally, Insilico will exhibit at the 9th China International Import Expo (CIIE) from November 5-10, 2026, where the company plans to use holographic projection technology to display its research and development pipeline.
The company's emphasis on "closed-loop workflows" and "automated experimental feedback loops" suggests that competitive advantage in AI drug discovery is shifting from model access alone to integrated platform capabilities and proprietary data assets. This operational maturation—from experimental tool to production-scale drug discovery engine—may signal a broader industry transition from promise to clinical delivery.
For healthcare providers and researchers, these developments indicate that AI-discovered molecules can progress through rigorous clinical validation, potentially compressing traditional preclinical timelines. For patients, faster candidate generation could expand treatment options for rare and complex diseases where current therapies remain limited.
Sources
Companies in this article
Google Search
Follow Health AI Central on Google
Choose Health AI Central as a preferred source, and Google is more likely to show our reporting in Top Stories.
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.